J Voglová

1.2k total citations
33 papers, 303 citations indexed

About

J Voglová is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, J Voglová has authored 33 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 23 papers in Hematology and 10 papers in Rheumatology. Recurrent topics in J Voglová's work include Chronic Lymphocytic Leukemia Research (19 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Eosinophilic Disorders and Syndromes (10 papers). J Voglová is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Eosinophilic Disorders and Syndromes (10 papers). J Voglová collaborates with scholars based in Czechia, Slovakia and Finland. J Voglová's co-authors include L Chrobák, Edgar Faber, Karel Indrák, R Neuwírtová, Jiřı́ Mayer, Hana Klamová, Павел Зак, Elena Tóthová, Peter Rohoň and Ladislav Dušek and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

J Voglová

29 papers receiving 290 citations

Peers

J Voglová
Ole Maywald Germany
Daigo Akahane Japan
Hoffbrand Av United Kingdom
H. L. Seewann Austria
Gioia Colafigli Italy
Sara Vieira Portugal
Allison Jeynes-Ellis United States
Shuqian Xu China
A. Megan Cornelison United States
AK Burnett United Kingdom
Ole Maywald Germany
J Voglová
Citations per year, relative to J Voglová J Voglová (= 1×) peers Ole Maywald

Countries citing papers authored by J Voglová

Since Specialization
Citations

This map shows the geographic impact of J Voglová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Voglová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Voglová more than expected).

Fields of papers citing papers by J Voglová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Voglová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Voglová. The network helps show where J Voglová may publish in the future.

Co-authorship network of co-authors of J Voglová

This figure shows the co-authorship network connecting the top 25 collaborators of J Voglová. A scholar is included among the top collaborators of J Voglová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Voglová. J Voglová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Žáčková, Daniela, Hana Klamová, Tereza Nečasová, et al.. (2020). Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leukemia & lymphoma. 62(1). 194–202.
2.
Steinerová, Kateřina, Michal Karas, Peter Rohoň, et al.. (2019). First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. Leukemia Research. 81. 67–74. 6 indexed citations
3.
Voglová, J, Zdeněk Ráčil, Daniela Žáčková, et al.. (2018). The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients. Archives of Medical Science. 14(6). 1416–1423. 14 indexed citations
4.
Maisnar, Vladimír, et al.. (2016). Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone. Acta Medica (Hradec Kralove Czech Republic). 59(2). 50–53. 4 indexed citations
5.
Voglová, J, et al.. (2015). [Impact of age on the clinical response of patients with CML treated with imatinib].. PubMed. 61(9). 785–6, 788. 2 indexed citations
6.
Zeidler, Cornelia, Ulrike Grote, Alexander Nickel, et al.. (2014). Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. Haematologica. 99(8). 1395–1402. 27 indexed citations
7.
Ráčil, Zdeněk, Petr Cetkovský, Edgar Faber, et al.. (2014). Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study. Blood. 124(21). 1813–1813. 10 indexed citations
8.
Voglová, J, Edgar Faber, Hana Klamová, et al.. (2011). Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma. 58(3). 256–262. 18 indexed citations
9.
Kreutzman, Anna, Peter Rohoň, Edgar Faber, et al.. (2011). Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. PLoS ONE. 6(8). e23022–e23022. 35 indexed citations
10.
11.
12.
13.
Maisnar, Vladimír, et al.. (2006). The significance of soluble CD138 in diagnosis of monoclonal gammopathies.. PubMed. 53(1). 26–9. 8 indexed citations
14.
Chrobák, L & J Voglová. (2003). Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML). Acta Medica (Hradec Kralove Czech Republic). 46(3). 85–89. 3 indexed citations
15.
Moravcová, Jana, Hana Klamová, J Voglová, et al.. (2003). Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia Research. 28(4). 415–419. 15 indexed citations
16.
17.
Hrdina, Radomír, Vladimír Geršl, J Vávrová, et al.. (1998). Myocardial elements content and cardiac function after repeated i.v. administration of DMPS in rabbits. Human & Experimental Toxicology. 17(4). 221–224. 5 indexed citations
18.
Geršl, Vladimír, Radomír Hrdina, J Vávrová, et al.. (1997). Effects of Repeated Administration of Dithiol Chelating Agent - Sodium 2,3-Dimercapto-1-propanesulphonate (DMPS) - On Biochemical and Haematological Parameters in Rabbits. Acta Medica (Hradec Kralove Czech Republic). 40(1). 3–8. 12 indexed citations
19.
Chrobak, Ł., et al.. (1996). [An unusual course in hairy-cell leukemia with marked abdominal lymphadenopathy, leukemic infiltration of the cornea and skin changes].. PubMed. 42(7). 463–6. 6 indexed citations
20.
Bajgar, J, Radomír Hrdina, J Vávrová, et al.. (1995). Changes of some biochemical and hematological parameters following administration of daunorubicin in rabbits.. PubMed. 38(2). 79–84.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ole Maywald Breakdown of academic impact, for papers by Daigo Akahane Breakdown of academic impact, for papers by Hoffbrand Av Breakdown of academic impact, for papers by H. L. Seewann Breakdown of academic impact, for papers by Gioia Colafigli Breakdown of academic impact, for papers by Sara Vieira Breakdown of academic impact, for papers by Allison Jeynes-Ellis Breakdown of academic impact, for papers by Shuqian Xu Breakdown of academic impact, for papers by A. Megan Cornelison Breakdown of academic impact, for papers by AK Burnett
Rankless by CCL
2026